# DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award

Source: https://welltoldgrants.com/grants/ht942525alsrpcoba-dod-amyotrophic-lateral-sclerosis-clinical-outcomes-and/  
Official notice: https://www.grants.gov/search-results-detail/358720

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 6 awards worth $6.3 million in total. Applications closed on August 27, 2025.

| Field | Value |
|---|---|
| Opportunity number | HT942525ALSRPCOBA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | August 27, 2025 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 6 |
| Total funding | $6.3 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. To meet the intent of the funding opportunity, applications must address ONE or BOTH of the following focus areas: Clinical Biomarkers: Identification, development, and/or validation of promising biomarkers for ALS. Biomarkers may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes: Identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include optimization of current outcome measures already in use. Both focus areas are permitted to utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Distinctive Features: Applications proposing prospective biospecimen collection or participant enrollment are required to incorporate a Community Collaboration, as described in Attachment 9.

## Questions people ask

### Is HT942525ALSRPCOBA still open?

No. It closed on August 27, 2025. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award?

Closed August 27, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $6.3 million in total across about 6 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.